Aug 10, 2018 Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update Learn More
Jul 31, 2018 Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Learn More
Jul 27, 2018 Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering Learn More
Jul 18, 2018 Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients Learn More